Vocinti

Treatment of gastric ulcer; duodenal ulcer; reflux esophagitis (erosive esophagitis). Maintenance treatment of reflux esophagitis (erosive esophagitis). Prevention of recurrence of gastric or duodenal ulcer during NSAID administration. Adjunct to H. pylori eradication.

Adult Treatment of gastric ulcer 20 mg once daily, limited to 8 wk. Treatment of duodenal ulcer 20 mg once daily, limited to 6 wk. Treatment of reflux esophagitis 20 mg once daily, limited to 4 wk. May continue for up to 8 wk when effect is insufficient. Maintenance treatment of recurrent & relapsed reflux esophagitis 10 mg once daily. May administer 20 mg once daily when efficacy is inadequate. Prevention of recurrence of gastric or duodenal ulcer during NSAID administration 10 mg once daily. Adjunct to H. pylori eradication 20 mg vonoprazan w/ amoxicillin & clarithromycin administered at the same time bd for 7 days. Alternatively, 20 mg vonoprazan w/ amoxicillin & metronidazole administered at the same time bd for 7 days when treatment w/ PPI, amoxicillin, & clarithromycin fails.

May be taken with or without food.

Hypersensitivity.

Reports of hepatic function abnormalities including liver injury. Discontinue in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction. Elevation of intragastric pH. Not recommended to be taken w/ drugs for which absorption is dependent on acidic intragastric pH. Masking of symptoms associated w/ gastric malignancy. Increased risk of Clostridium difficile GI infection. Risk of serious colitis accompanied w/ bloody stools (eg, pseudomembranous colitis) due to combination w/ amoxicillin or clarithromycin for H. pylori eradication. Risk of benign gastric polyps in patients on long-term administration. Increased risk for osteoporosis-related fractures of the hip, wrist or spine, especially in patients receiving high-dose or long-term treatment. Reports of severe hypomagnesaemia in patients on prolonged treatment. Unknown influence on the ability to drive or use machines. Carefully administer in patients w/ renal or hepatic disorders, & the elderly. Should not be administered to women who are or may be pregnant, unless expected benefit outweighs possible risk. Nursing should be avoided if treatment is necessary for the mother. Has not been studied in patients <18 yr.

Diarrhoea, constipation.

Significantly reduced bioavailability of drugs for which absorption is dependent on acidic intragastric pH eg, atazanavir & nelfinavir. Increased blood conc w/ strong CYP3A4 inhibitors eg, clarithromycin. Increased conc w/ clarithromycin & amoxicillin. Increased conc of midazolam & other sensitive CYP3A4 substrates, notably those w/ narrow therapeutic index.

Antacids, Antireflux Agents & Antiulcerants

A02BC08 - vonoprazan ; Belongs to the class of potassium-competitive acid blocker. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

P₁S₁S₃